<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04068207</url>
  </required_header>
  <id_info>
    <org_study_id>5010-MINO-RP</org_study_id>
    <nct_id>NCT04068207</nct_id>
  </id_info>
  <brief_title>Minocycline Treatment in Retinitis Pigmentosa</brief_title>
  <official_title>The Efficacy and Safety of Oral Minocycline in the Treatment of Retinitis Pigmentosa: An Open-label Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy and safety of oral minocycline (100mg/d),&#xD;
      administered for 6 months, for the treatment of patients with retinitis pigments(RP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retinitis Pigmentosa (RP)is a sort of inherited blinding disorders and no effective or safe&#xD;
      treatment are widely applied for it. The worldwide prevalence of RP is estimated to be&#xD;
      1/5000. RP is characterized by degeneration of peripheral rod photoreceptor(PR) and&#xD;
      associated retinal pigment epithelium(RPE) cells. Nyctalopia and visual field constriction&#xD;
      are common symptoms. Cone degeneration and associated loss of central vision are typically&#xD;
      followed later.&#xD;
&#xD;
      Minocycline, a secord-generation, semi-synthetic tetracycline antibiotic, is a highly&#xD;
      lipophilic molecule and can easily pass through the blood-brain barrier. Several animal&#xD;
      experiments and clinical trials have reported that minocycline exert anti-apoptotic,&#xD;
      anti-inflammatory and antioxidant effects in treating neurodegenerative diseases.&#xD;
&#xD;
      We propose to test the effect and safety of oral minocycline for retinitis pigmentosa.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Actual">September 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of full-field cone electroretinogram amplitude to 30-Hz flashes</measure>
    <time_frame>24 weeks</time_frame>
    <description>increase of full-field cone electroretinogram amplitude to 30-Hz flashes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of visual field area</measure>
    <time_frame>24 weeks</time_frame>
    <description>HFA30-2 and HFA60-4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>24 weeks</time_frame>
    <description>increase of BCVA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>central foveal thickness</measure>
    <time_frame>24 weeks</time_frame>
    <description>increase of central foveal thickness</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <condition>Inherited Retinal Dystrophy</condition>
  <condition>Retina Disorder</condition>
  <arm_group>
    <arm_group_label>Minocycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets Minocycline 100mg po per day for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>Tab. Minocycline 100mg po per day for 24 weeks</description>
    <arm_group_label>Minocycline</arm_group_label>
    <other_name>Minocin</other_name>
    <other_name>Minocyclinum</other_name>
    <other_name>Minocyclin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of Retinitis Pigmentosa: nyctalopia, visual field constriction and&#xD;
             loss of central vision; degeneration of peripheral rod photoreceptor and retinal&#xD;
             pigment epithelium cells.&#xD;
&#xD;
          -  Age from 18 to 60 years old.&#xD;
&#xD;
          -  BCVA &gt;20/100(0.2).&#xD;
&#xD;
          -  Full-field cone electroretinogram amplitude to 30-Hz flashes &gt;0uV.&#xD;
&#xD;
          -  Written informed consent is provided.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Glucocortticoids or tetracycline were used within 3 months.&#xD;
&#xD;
          -  Vitamin A, DHA and other neurotrophic drugs were used within 3 months.&#xD;
&#xD;
          -  Other ocular diseases or fundus diseases except cataract: glaucoma, diabetic&#xD;
             retinopathy, retinal detachment.&#xD;
&#xD;
          -  Tetracycline or minocycline allergy or intolerance.&#xD;
&#xD;
          -  Renal or hepatic insufficiency.&#xD;
&#xD;
          -  History of thyroid neoplasm.&#xD;
&#xD;
          -  History of idiopathic intracranial hypertension.&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Liang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dan Liang, MD</last_name>
    <phone>0086-20-87330402</phone>
    <email>liangd2@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Liang, MD</last_name>
      <phone>0086-20-87330402</phone>
      <email>liangd2@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Dan Liang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Liang</last_name>
      <phone>0086-20-87330402</phone>
      <email>liangd2@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Dan Liang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 23, 2019</study_first_submitted>
  <study_first_submitted_qc>August 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Dan Liang</investigator_full_name>
    <investigator_title>Lab of ocular immunology in Zhongshan Ophthalmic Center</investigator_title>
  </responsible_party>
  <keyword>Retinitis Pigmentosa</keyword>
  <keyword>Minocycline</keyword>
  <keyword>ERG</keyword>
  <keyword>Inherited Retinal Dystrophy</keyword>
  <keyword>Retinal Degenerative Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Retinal Dystrophies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

